A Phase Ib/IIa, Open-Label, Dose Finding Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3Kβ Selective Inhibitor (GSK2636771) Administered in Combination With Paclitaxel in Advanced Gastric Adenocarcinoma Having Alterations in PI3K Pathway Genes
Phase of Trial: Phase I/II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs GSK 2636771 (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 10 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 12 Jul 2016 Status changed from not yet recruiting to recruiting.